Go Pro
→ Everyone remembers January's silver spike. Then what? (From i2i Marketing Group, LLC) (Ad)tc pixel Free NKGN Stock Alerts

NKGen Biotech (NKGN) Competitors

NKGen Biotech logo
$0.01 0.00 (0.00%)
As of 09/22/2026 03:27 PM Eastern
Compare

NKGN vs. NMTR, EVFM, JAGX, PRFX, and HEPA

Should you buy NKGen Biotech stock or one of its competitors? NKGen Biotech's main competitors and comparable companies include 9 Meters Biopharma (NMTR), Evofem Biosciences (EVFM), Jaguar Animal Health (JAGX), PainReform (PRFX), and Hepion Pharmaceuticals (HEPA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NKGen Biotech compare to 9 Meters Biopharma?

NKGen Biotech (NYSE:NKGN) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NKGen Biotech is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
9 Meters Biopharma Neutral

NKGen Biotech's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
9 Meters Biopharma N/A -584.97%-159.45%

NKGen Biotech has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Summary

NKGen Biotech and 9 Meters Biopharma tied by winning 4 of the 8 factors compared between the two stocks.

How does NKGen Biotech compare to Evofem Biosciences?

NKGen Biotech (NYSE:NKGN) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Evofem Biosciences had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for NKGen Biotech. NKGen Biotech's average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Evofem Biosciences Neutral

NKGen Biotech has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market.

NKGen Biotech has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. NKGen Biotech's return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Evofem Biosciences -46.42%-91.97%-61.93%

Evofem Biosciences has higher revenue and earnings than NKGen Biotech. Evofem Biosciences is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
Evofem Biosciences$11.39M0.09$52.98M-$0.13N/A

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

NKGen Biotech beats Evofem Biosciences on 6 of the 11 factors compared between the two stocks.

How does NKGen Biotech compare to Jaguar Animal Health?

NKGen Biotech (NYSE:NKGN) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

NKGen Biotech has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Jaguar Animal Health -187.88%N/A -131.45%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Jaguar Animal Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Jaguar Animal Health has higher revenue and earnings than NKGen Biotech. Jaguar Animal Health is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
Jaguar Animal Health$11.51M0.26-$53.43M-$248.88N/A

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 0.2% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NKGen Biotech has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

In the previous week, Jaguar Animal Health had 17 more articles in the media than NKGen Biotech. MarketBeat recorded 17 mentions for Jaguar Animal Health and 0 mentions for NKGen Biotech. NKGen Biotech's average media sentiment score of 0.00 beat Jaguar Animal Health's score of -0.11 indicating that NKGen Biotech is being referred to more favorably in the media.

Company Overall Sentiment
NKGen Biotech Neutral
Jaguar Animal Health Neutral

Summary

NKGen Biotech beats Jaguar Animal Health on 7 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to PainReform?

NKGen Biotech (NYSE:NKGN) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PainReform
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
PainReform Neutral

NKGen Biotech has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, PainReform has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
PainReform N/A N/A N/A

PainReform has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
PainReform$31K28.03-$5.02M-$736.66N/A

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

PainReform beats NKGen Biotech on 7 of the 9 factors compared between the two stocks.

How does NKGen Biotech compare to Hepion Pharmaceuticals?

NKGen Biotech (NYSE:NKGN) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

NKGen Biotech is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Hepion Pharmaceuticals Neutral

NKGen Biotech has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NKGen Biotech's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Hepion Pharmaceuticals N/A -812.56%-207.31%

Summary

NKGen Biotech beats Hepion Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGN vs. The Competition

Export
MetricNKGen BiotechPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$1.57M$12.61B$7.32B$23.07B
Dividend YieldN/A2.63%2.52%3.61%
P/E Ratio0.00792.28274.0628.10
Price / SalesN/A860.49637.8115.59
Price / CashN/A88.6477.8038.68
Price / Book0.0010.5910.404.66
Net Income-$82.94M$2.81B$3.49B$1.07B
7 Day PerformanceN/A-0.14%-0.69%-1.27%
1 Month PerformanceN/A-1.36%-3.18%-4.71%
1 Year PerformanceN/A2.85%15.13%7.48%

NKGen Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGN
NKGen Biotech
N/A$0.01
flat		N/A-89.1%$1.57MN/AN/AN/A
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
EVFM
Evofem Biosciences
N/A$0.01
-5.1%		N/A-46.9%$981K$11.39MN/A120
JAGX
Jaguar Animal Health
0.4018 of 5 stars		$2.71
-1.5%		N/A-99.2%$950K$11.51MN/A47
PRFX
PainReform
0.7225 of 5 stars		$1.02
flat		N/A-86.8%$890K$20KN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel